Patent ID: 7927613

Claim:
A co-crystal comprising an API and a co-crystal former selected from: (a) carbamazepine and saccharin; (b) carbamazepine and nicotinamide; (c) carbamazepine and trimesic acid; (d) celecoxib and nicotinamide; (e) celecoxib and 18-crown-6; (f) 5-fluorouracil and urea; (g) acetaminophen and 4,4′-bipyridine; (h) phenytoin and pyridone; (i) aspirin and 4,4′-bipyridine; (j) ibuprofen and 4,4′-bipyridine; (k) flurbiprofen and 4,4′-bipyridine; (l) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene; (m) carbamazepine and p-phthalaldehyde; (n) carbamazepine and 2,6-pyridinecarboxylic acid; (o) carbamazepine and 5-nitroisoplithalic acid; (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or (q) carbamazepine and benzoquinone, wherein the API and co-crystal former are hydrogen bonded to each other.